You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 18, 2025

Mechanism of Action: Vesicular Monoamine Transporter 2 Inhibitors


✉ Email this page to a colleague

« Back to Dashboard


Drugs with Mechanism of Action: Vesicular Monoamine Transporter 2 Inhibitors

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 AB RX Yes No 10,065,952 ⤷  Try for Free Y Y ⤷  Try for Free
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-003 Apr 23, 2021 RX Yes No 11,026,939 ⤷  Try for Free Y ⤷  Try for Free
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-003 Apr 23, 2021 RX Yes No 10,906,902 ⤷  Try for Free Y Y ⤷  Try for Free
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 AB RX Yes Yes 11,654,142 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Vesicular Monoamine Transporter 2 Inhibitors Market Analysis and Financial Projection

The market for Vesicular Monoamine Transporter 2 (VMAT2) inhibitors is experiencing dynamic growth driven by unmet clinical needs and therapeutic innovation, while the patent landscape reflects intense competition and strategic intellectual property management.


Market Dynamics

Growth Drivers

  • Rising Disease Prevalence: The increasing incidence of Huntington’s disease (affecting ~5-10 per 100,000 people globally) and tardive dyskinesia (~500,000 U.S. cases) is a primary growth driver[1][10].
  • Therapeutic Advancements: Next-generation inhibitors like valbenazine (Ingrezza) and deutetrabenazine (Austedo) offer improved safety profiles and compliance, with Neurocrine Biosciences’ Ingrezza Sprinkle capsules enhancing ease of administration[12][13].
  • Regional Expansion: North America dominates the market (45-50% share) due to advanced healthcare infrastructure and high diagnosis rates. Asia-Pacific is emerging as a high-growth region with increasing investments in neurological research[1][6].

Market Challenges

  • Regulatory Hurdles: Stringent approval processes and post-marketing surveillance requirements delay commercialization[1][10].
  • Side Effects: Dose-dependent risks like sedation and QT prolongation limit broader adoption[1][4].
  • Generic Competition: Patent expirations, such as tetrabenazine’s loss of exclusivity, intensify pricing pressures[5][12].

Projected Growth:

  • The market is expected to grow from $1.13 billion in 2024 to $1.85 billion by 2029 at a 10.3% CAGR, fueled by personalized medicine and digital health integration[12].

Patent Landscape

Key Innovations and IP Strategies

  • Neurocrine Biosciences: Secured composition-of-matter patents for valbenazine (extending to 2029) and methods of administration[9][11]. Their IP portfolio includes dosing protocols to minimize side effects, such as once-daily formulations[11].
  • Therapeutic Expansion: Patents cover novel applications, including Alzheimer’s-related agitation (US20190015396A1)[2], psychostimulant abuse treatment (US10,668,030)[8], and mood disorders (WO2016210180A2)[7].
  • Competitive Filings: Over 120 patents filed globally since 2017, with China, the U.S., and Japan leading innovation. Small-molecule inhibitors dominate R&D pipelines[5][10].

Notable Patent Trends

  • Abandoned Applications: Early-stage candidates like US20190015396A1 (targeting Alzheimer’s agitation) were abandoned, highlighting clinical trial risks[2].
  • University Contributions: Academic institutions like the University of Kentucky patented VMAT2 ligands for substance abuse treatment, underscoring cross-sector collaborations[8].

Competitive Landscape and Key Players

Market Leaders

  1. Neurocrine Biosciences: Holds ~35% market share with Ingrezza, targeting tardive dyskinesia and Huntington’s chorea[9][12].
  2. Teva Pharmaceutical: Markets Austedo (deutetrabenazine), focusing on lifecycle management through new indications[1][5].
  3. Sun Pharma and Hikma: Compete via generics and regional distribution networks in Asia and Africa[1][6].

Strategic Developments

  • Clinical Trials: Neurocrine’s NBI-921852 (Phase III for epilepsy) and Luye Pharma’s LY03015 (Phase II for schizophrenia) aim to diversify applications[1][10].
  • M&A Activity: Consolidation is rising, with companies like Lundbeck acquiring niche players to expand CNS portfolios[6][10].

Future Outlook

  • Next-Gen Inhibitors: Drugs with reduced off-target effects and once-weekly dosing (e.g., Neurocrine’s NBI-98854) are under development[13].
  • Digital Integration: Wearables for real-time symptom monitoring and AI-driven dosing optimization are emerging trends[12].
  • Global Accessibility: Partnerships with generics manufacturers aim to lower costs in underserved regions like Southeast Asia[6][10].

Highlight: "VMAT2 inhibitors represent a paradigm shift in managing hyperkinetic movement disorders, combining targeted action with improved tolerability." — Market Dynamics Report, 2025[10]

This evolving landscape underscores the intersection of clinical innovation and strategic IP management, positioning VMAT2 inhibitors as critical tools in neurology and psychiatry.

References

  1. https://www.datainsightsmarket.com/reports/vmat2-inhibitors-338940
  2. https://patents.google.com/patent/US20190015396A1/en
  3. https://en.wikipedia.org/wiki/Vesicular_monoamine_transporter_2
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4084610/
  5. https://synapse.patsnap.com/blog/what-are-vmat2-inhibitors-and-how-do-you-quickly-get-the-latest-development-progress
  6. https://www.360iresearch.com/library/intelligence/vmat2-inhibitor
  7. https://patents.google.com/patent/WO2016210180A2/en
  8. https://uknowledge.uky.edu/ps_patents/189/
  9. https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-notice-allowance-composition
  10. https://markwideresearch.com/vesicular-monoamine-transporter-2-inhibitors-vmat2-inhibitors-market/
  11. https://patentimages.storage.googleapis.com/0d/70/26/d81cc92889dc55/US10857148.pdf
  12. https://www.thebusinessresearchcompany.com/market-insights/vesicular-monoamine-transporter-2-vmat2-inhibitor-market-overview-2025
  13. https://www.biospace.com/neurocrine-biosciences-inc-announces-that-vmat2-program-will-move-into-phase-ii-clinical-trials
Last updated: 2025-03-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.